Literature DB >> 15647926

Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses.

Thomas Felzmann1, Katharina Gabriele Hüttner, Sabine Konstanze Breuer, Doris Wimmer, Gabriele Ressmann, Dagmar Wagner, Petra Paul, Manfred Lehner, Andreas Heitger, Wolfgang Holter.   

Abstract

Dendritic cells (DC) are candidates for antigen-presenting cells that present exogenous antigen on MHC class I molecules to cytotoxic T lymphocytes (CTL), a process referred to as cross-priming. We triggered interleukin (IL)-12 release from DC, which was limited to the first day after maturation induction, by a combination of lipopolysaccharide (LPS) and interferon (IFN)-gamma. To stimulate T lymphocytes, we used soluble protein derived from lysis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCL) or ovalbumin loaded onto DC. Co-culture was initiated 2-6 or 48 h after maturation corresponding to "semi-mature" actively IL-12-secreting type 1 DC (sm-DC1) or a "fully mature" DC1 that had lost the ability to release IL-12 (fm-DC1), respectively. IL-12-secreting sm-DC1 but not fm-DC1 efficiently triggered cytolytic activity in autologous T lymphocytes. The combination of IL-1beta, IL-6, TNF-alpha, and prostaglandin E2 generated type 2 DC that did not secrete IL-12 (DC2) and could not prime T-cell cytolytic activity. However, supplementation of cultures using DC2 with IL-12 resulted in CTL activity while the presence of anti-IL-12 monoclonal antibodies in cultures using IL-12 secreting sm-DC1 suppressed CTL activity. Thus, actively IL-12-secreting sm-DC1 are necessary and sufficient for the antigen-specific expansion of CTL in response to exogenously provided soluble antigen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15647926     DOI: 10.1007/s00262-004-0637-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  14 in total

Review 1.  Monocyte-derived DC maturation strategies and related pathways: a transcriptional view.

Authors:  Luciano Castiello; Marianna Sabatino; Ping Jin; Carol Clayberger; Francesco M Marincola; Alan M Krensky; David F Stroncek
Journal:  Cancer Immunol Immunother       Date:  2011-01-22       Impact factor: 6.968

Review 2.  The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.

Authors:  Amy B Hont; Allison B Powell; Danielle K Sohai; Izabella K Valdez; Maja Stanojevic; Ashley E Geiger; Kajal Chaudhary; Ehsan Dowlati; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Mol Ther       Date:  2022-02-09       Impact factor: 12.910

3.  Indoleamine 2,3-dioxygenase in human hematopoietic stem cell transplantation.

Authors:  Birgit Jürgens; Julia Raberger; Dietmar Fuchs; Andreas Heitger
Journal:  Int J Tryptophan Res       Date:  2010-06-10

4.  MicroRNA profiling of activated and tolerogenic human dendritic cells.

Authors:  Zuzana Stumpfova; Renata Hezova; Albano Carlo Meli; Ondrej Slaby; Jaroslav Michalek
Journal:  Mediators Inflamm       Date:  2014-04-01       Impact factor: 4.711

5.  Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.

Authors:  Friedrich Erhart; Johanna Buchroithner; René Reitermaier; Katrin Fischhuber; Simone Klingenbrunner; Ido Sloma; Dror Hibsh; Renana Kozol; Sol Efroni; Gerda Ricken; Adelheid Wöhrer; Christine Haberler; Johannes Hainfellner; Günther Krumpl; Thomas Felzmann; Alexander M Dohnal; Christine Marosi; Carmen Visus
Journal:  Acta Neuropathol Commun       Date:  2018-12-05       Impact factor: 7.801

6.  Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses.

Authors:  Ellen Van Gulck; Nathalie Cools; Derek Atkinson; Lotte Bracke; Katleen Vereecken; Marc Vekemans; Viggo F I Van Tendeloo; Zwi N Berneman; Guido Vanham
Journal:  Clin Dev Immunol       Date:  2012-07-12

7.  Toll-like receptor 4 engagement drives differentiation of human and murine dendritic cells from a pro- into an anti-inflammatory mode.

Authors:  Romana Luger; Sneha Valookaran; Natalie Knapp; Caterina Vizzardelli; Alexander M Dohnal; Thomas Felzmann
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

8.  Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines.

Authors:  Alexander Michael Dohnal; Sebastian Graffi; Volker Witt; Christina Eichstill; Dagmar Wagner; Sidrah Ul-Haq; Doris Wimmer; Thomas Felzmann
Journal:  J Cell Mol Med       Date:  2008-03-17       Impact factor: 5.310

9.  Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy.

Authors:  Katerina Vopenkova; Klara Mollova; Ivana Buresova; Jaroslav Michalek
Journal:  J Cell Mol Med       Date:  2012-11       Impact factor: 5.310

10.  Dendritic cell-secreted lipocalin2 induces CD8+ T-cell apoptosis, contributes to T-cell priming and leads to a TH1 phenotype.

Authors:  Melanie Floderer; Michaela Prchal-Murphy; Caterina Vizzardelli
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.